Federal Circuit Focuses On Active Ingredient, Not Active Moiety, For Scope Of Patent Term Extension

Published date30 June 2020
Subject MatterFDA,Patents,Hatch-Waxman,Pfizer,Patent Litigation,Pharmaceutical Patents,Patent Term Extensions
AuthorCourtenay C. Brinckerhoff
Law FirmFoley & Lardner LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT